Deltex Medical Group plc
DTXMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $2 |
| % Growth | 15.8% | -28.4% | 9.9% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $1 | $1 | $2 | $2 |
| % Margin | 68% | 63.3% | 74.1% | 69.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $3 | $2 | $3 | $2 |
| Operating Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -77.1% | -59.2% | -38.2% | -35.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -87.4% | -72.2% | -46.1% | -42.8% |
| EPS | -0.001 | -0.001 | -0.002 | -0.002 |
| % Growth | 18.2% | 35.3% | 0% | – |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.002 |
| Weighted Avg Shares Out | 1,896 | 1,182 | 685 | 581 |
| Weighted Avg Shares Out Dil | 1,894 | 1,181 | 685 | 581 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -39.3% | -51.7% | -33% | -30.6% |